http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006034080-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e21f8adfe2eb504c606728e1506851af http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c3ac6221b5b90dda13d5e9c2c7526e51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dbe6a152ab369ec0c2c593941a1ee036 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1694 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-26 |
| filingDate | 2005-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b4983208f6bea49131facc02de113f2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa072640f730ed0a43bec91dbb50057f |
| publicationDate | 2006-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2006034080-A2 |
| titleOfInvention | Formulation comprising itraconazole |
| abstract | Formulations of azole antifungals such as itraconazole and particularly formulations, coformulations and compositions of itraconazole with one or more oligomeric and/or polymeric excipients are disclosed. Methods for preparation of the formulations, co-formulations and compositions include co-precipitating the two materials from a common solvent or solvent mixture using a compressed (typically supercritical or near-critical) fluid anti-solvent as in the GAS (Gas Anti-Solvent) precipitation method. The formulations, co-formulations, compositions, methods of making and methods of delivering, are useful as pharmaceutical compositions and in medical treatment by virtue of their at least parity, preferably improved or enhanced solubility or dissolution characteristics, resulting in at least parity, preferably improved or enhanced bioavailability and/or pharmacokinetics. |
| priorityDate | 2004-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 116.